Skip to content
PeptideAgent

Clinics in Connecticut

By the PeptideAgent Editorial Team. Draft, pending editorial review.  Last verified

What Connecticut law means for peptide clinics: who may prescribe, whether pharmacies may compound GLP-1 drugs (limited), how to check a clinic, and verified listings.

Connecticut at a glance

503A framework
Follows the federal 503A framework
Telehealth prescribing
Regulatory: Telehealth allowed
Asynchronous prescribing
Regulatory: Async allowed
Compounded GLP-1 access
Regulatory: Compounded GLP-1 limited

Verified clinics serving Connecticut

No verified clinics serving Connecticut are listed yet. A provider appears here only after it passes the verification checklist, and those checks are still under way.

Looking for care now? Start with what the law allows where you live, then how a legitimate prescription works.

Run a pharmacy, clinic, or telehealth service? Apply for a listing.

Peptide access rules in Connecticut

Yes. A Connecticut resident can obtain FDA approved peptides such as semaglutide and tirzepatide by prescription from a Connecticut-licensed provider, including by telehealth under Connecticut General Statutes section 19a-906, which covers synchronous, asynchronous store-and-forward, and remote monitoring care. Compounded peptides are available when eligible under federal 503A rules and dispensed by a Connecticut pharmacy or a registered nonresident pharmacy; a nonresident pharmacy that compounds sterile products such as injectable peptides for Connecticut patients must file a sterile compounding addendum and receive written approval from the Department of Consumer Protection and the Commission of Pharmacy first (section 20-633b). [1] [2] [3] [4] [5] [6] [7] [9]

Compounded GLP-1 access in Connecticut

Because compounded GLP-1 injections are sterile preparations, an out-of-state pharmacy shipping them to Connecticut must have an approved sterile compounding addendum under section 20-633b in addition to its nonresident registration. [5] [6] [10]

Research use only sellers in Connecticut

Only Connecticut-licensed pharmacies and registered nonresident pharmacies may dispense prescription drugs to Connecticut patients. "Research use only" peptides sold for human injection are unapproved new drugs under federal law, are not dispensed by a pharmacist, and fall outside Connecticut's sterile compounding approval system. Connecticut law also bars the sale directly: under the Connecticut Food, Drug and Cosmetic Act, section 21a-110 provides that no person shall sell, deliver, offer for sale, hold for sale, or give away any new drug unless an application for it has been approved under section 355 of the federal act or, for a drug not subject to the federal act, a state application has been filed with the Commissioner of Consumer Protection. The Connecticut Attorney General has used the Connecticut Unfair Trade Practices Act (Conn. Gen. Stat. 42-110a and following) against sellers of research-grade GLP-1s, including a 2025 settlement with an online distributor and a May 2026 settlement under which an international online trade platform agreed to stop GLP-1 sales to US consumers and remove such listings. The same May 2026 announcement included a settlement with a medical spa that stopped advertising and prescribing compounded semaglutide and tirzepatide. [5] [8] [11] [12]

Connecticut notes on specific peptides

  • Semaglutide: Available branded by prescription, including after an asynchronous telehealth evaluation under section 19a-906. Compounded semaglutide is limited to documented patient-specific needs since the 503A grace period ended April 22, 2025, and out-of-state compounded vials require an approved sterile compounding addendum. [2] [6] [10]

How to check a clinic in Connecticut

  1. Confirm the prescribing clinician's license with the Connecticut medical or nursing board.
  2. Ask which pharmacy compounds or dispenses the peptide and check it in the Connecticut Commission of Pharmacy (Department of Consumer Protection, Drug Control Division) license lookup. [1] [4] [5] [6] [7] [9]
  3. Confirm the peptide can be lawfully compounded: check its status on the regulatory tracker or its peptide page before paying.
  4. Walk away from any seller that labels a peptide "research use only" or "not for human consumption". See the research use only section above for what that means in Connecticut. [5] [8] [11] [12]

Common questions in Connecticut

Does Connecticut allow asynchronous telehealth prescribing for GLP-1 drugs?

Yes. Section 19a-906 defines telehealth to include asynchronous store and forward transfers, and semaglutide and tirzepatide are not controlled substances, so a Connecticut-licensed provider may prescribe them after an evaluation that meets the in-person standard of care and includes access to your medical history. [2]

Can an out-of-state telehealth doctor still treat me in Connecticut?

Generally only with a Connecticut license. The temporary out-of-state authorization in section 19a-906 ran through June 30, 2025. Check the provider on the Department of Public Health license lookup before paying. [2] [3]

All peptide legal questions for Connecticut

Sources

  1. [1]Connecticut Commission of Pharmacy, Department of Consumer Protection
  2. [2]Connecticut General Statutes section 19a-906, Telehealth services
  3. [3]Connecticut General Statutes chapter 368ll (current text of section 19a-906)
  4. [4]Connecticut General Statutes chapter 400j, Pharmacy
  5. [5]Connecticut General Statutes section 20-627, Nonresident pharmacy registration
  6. [6]Connecticut General Statutes section 20-633b, Sterile compounding pharmacies
  7. [7]Regulations of Connecticut State Agencies sections 20-576-64 to 20-576-68, Sterile compounding pharmacies (standards in section 20-576-66, adopted effective July 12, 2011), accessed 2026-09-22
  8. [8]Connecticut General Statutes chapter 418 (Connecticut Food, Drug and Cosmetic Act), section 21a-110, New drugs, accessed 2026-09-22
  9. [9]FDA: Section 503A of the Federal Food, Drug, and Cosmetic ActFDA
  10. [10]FDA: concerns with unapproved GLP-1 drugs used for weight loss, including shortage resolution and compounding grace periodsFDA
  11. [11]21 U.S.C. 331, Prohibited acts
  12. [12]Connecticut Attorney General: Online Platform to Cease Bootleg GLP-1 Weight Loss Drug Sales Nationwide (May 6, 2026)